Oxigene (OXGN) says the European Medicines Agency has granted orphan drug status to its ovarian...


Oxigene (OXGN) says the European Medicines Agency has granted orphan drug status to its ovarian cancer treatment Zybrestat. Data from a Phase 2 trial testing the combination of Zybrestat and Roche's (RHHBY.OB) cancer drug Avastin - to treat advanced ovarian cancer - could be available in early 2014. If the results prove positive, it could provide the basis for a registration program. Shares +32% AH.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs